15 completed, 8 terminated, 1 withdrawn. 9 Phase 3, 5 Phase 2, 4 Phase 1, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Terminated 5, Completed 4 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 4 | 3 | Terminated 2, Completed 1 |
Follow ezogabine: new trials by email Literature Review of ezogabine trials Research Report on ezogabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE XEN496 - Epilepsy, Epilepsy in Children | Phase 3 | Terminated | Xenon Pharmaceuticals Inc. | 8 | 2021-08-17 | 2025-02-14 |
| XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy XEN496, Placebo - Epilepsy, Epilepsy in Children | Phase 3 | Terminated | Xenon Pharmaceuticals Inc. | 8 | 2021-03-29 | 2024-08-23 |
| Study to Treat Major Depressive Disorder With a New Medication Ezogabine, Placebos - Depressive Disorder, Anhedonia | Phase 2 | Completed | James Murrough | 45 | 2017-09-25 | 2020-10-23 |
| Clinical Trial of Ezogabine (Retigabine) in ALS Subjects Ezogabine, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Brian Wainger | 65 | 2015-06-01 | 2019-08-28 |
| Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis Robotic Total Gastrectomy and Laparoscopic Total Gastrectomy - Advanced Gastric Cancer | Completed | Fujian Medical University | 1099 | 2015-01-01 | 2025-04-23 | |
| Study to Treat Major Depressive Disorder (MDD) With a New Medication ezogabine - Major Depressive Disorder, Depression | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 18 | 2014-08-01 | 2019-04-16 |
| Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study retigabine, placebo - Epilepsy | Phase 3 | Completed | University Hospital of Mont-Godinne | 15 | 2013-04-01 | 2014-12-02 |
| An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures ezogabine/retigabine - Epilepsy | Phase 4 | Terminated | GlaxoSmithKline | 10 | 2013-03-27 | 2020-12-04 |
| Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures Ezogabine/Retigabine IR, Placebo - Seizures | Phase 4 | Terminated | GlaxoSmithKline | 6 | 2012-12-19 | 2020-12-30 |
| Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects Retigabine - Epilepsy, Partial | Phase 1 | Withdrawn | GlaxoSmithKline | 2012-10-10 | 2018-09-17 | |
| Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS retigabine/ezogabine - Epilepsy | Phase 3 | Terminated | GlaxoSmithKline | 4 | 2012-09-04 | 2020-10-30 |
| Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures Retigabine 900mg/day, Retigabine 600mg/day, Placebo - Epilepsy | Phase 3 | Terminated | GlaxoSmithKline | 76 | 2012-08-29 | 2018-08-13 |
| Study in Pediatric Subjects With Epilepsy ezogabine/retigabine - Epilepsy | Phase 2 | Terminated | GlaxoSmithKline | 5 | 2012-07-25 | 2020-11-30 |
| Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects 50mg Ezogabine/retigabine, 100mg Ezogabine/retigabine, 200mg Ezogabine/retigabine - Epilepsy | Phase 1 | Completed | GlaxoSmithKline | 1 | 2012-04-10 | 2018-06-19 |
| An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed Digoxin Alone, Digoxin + Retigabine - Epilepsy | Phase 1 | Completed | GlaxoSmithKline | 30 | 2012-01-16 | 2018-06-19 |
| Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite Retigabine / Ezogabine - Epilepsy | Phase 1 | Completed | GlaxoSmithKline | 8 | 2011-11-30 | 2018-06-19 |
| Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304 retigabine/ezogabine - Epilepsy, Partial | Completed | GlaxoSmithKline | 1 | 2011-08-01 | 2012-10-29 | |
| Bioavailability of Different n-3 Fatty Acid Formulations rTG, GArTG, EE - Health | Phase 4 | Completed | Gottfried Wilhelm Leibniz Universität Hannover | 12 | 2010-10-01 | 2011-12-07 |
| Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy retigabine/ezogabine, lacosamide, zonisamide - Epilepsy | Completed | GlaxoSmithKline | 6498 | 2010-09-01 | 2013-09-16 | |
| Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) Retigabine, Placebo - Postherpetic Neuralgia | Phase 2 | Completed | Bausch Health Americas, Inc. | 187 | 2007-10-01 | 2018-05-08 |
Showing 20 of 24. Sign in to see all of them.
Epilepsy (17) · Seizures (7) · Epilepsies, Partial (4) · Brain Diseases (2) · Central Nervous System Diseases (2) · Depression (2) · Disease (2) · Epileptic Syndromes (2) · Nervous System Diseases (2) · Amyotrophic Lateral Sclerosis (1) · Anhedonia (1) · Depressive Disorder (1) · Depressive Disorder, Major (1) · Herpes Zoster (1) · Lennox Gastaut Syndrome (1)
GlaxoSmithKline (15) · Xenon Pharmaceuticals Inc. (2) · Bausch Health Americas, Inc. (1) · Brian Wainger (1) · Fujian Medical University (1) · Gottfried Wilhelm Leibniz Universität Hannover (1) · Icahn School of Medicine at Mount Sinai (1) · James Murrough (1) · University Hospital of Mont-Godinne (1)
United States (15) · Belgium (5) · Australia (4) · France (3) · Germany (3) · Poland (3) · South Africa (3) · Spain (3) · Argentina (2) · Brazil (2) · Canada (2) · Hungary (2) · Israel (2) · Mexico (2) · Russia (2)
Andreas Hahn, Prof. (1) · Brian Wainger, MD, PhD (1) · David Lineberry (1) · James Murrough, MD (1) · James Murrough, MD, PhD (1) · Michel Ossemann, MD (1)
PMID 22512894, PMID 33226425, PMID 33653118
R61MH111932 (1)